M
Mckenna Sean D
Researcher at Merck Serono
Publications - 28
Citations - 886
Mckenna Sean D is an academic researcher from Merck Serono. The author has contributed to research in topics: Antibody & Receptor. The author has an hindex of 15, co-authored 28 publications receiving 847 citations. Previous affiliations of Mckenna Sean D include Merck & Co..
Papers
More filters
Patent
Anti-pd-l1 antibodies and uses thereof
Nastri Horacio G,Christel Iffland,Olivier Leger,An Qi,Mark Cartwright,Mckenna Sean D,Vanita D. Sood,Hao Gang +7 more
TL;DR: In this paper, anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity.
Journal ArticleDOI
Evidence for Follicle-stimulating Hormone Receptor as a Functional Trimer.
Xuliang Jiang,David J. Fischer,Xiaoyan Chen,Mckenna Sean D,Heli Liu,Venkataraman Sriraman,Henry Yu,Andreas Goutopoulos,Steve Arkinstall,Xiaolin He +9 more
TL;DR: Evidence is presented confirming predictions that FSHR exists as a functional trimer and providing a mechanistic explanation to the agonist and antagonist activities of thyroid-stimulating hormone receptor autoantibodies.
Journal ArticleDOI
Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats
Mckenna Sean D,Michael Pietropaolo,Enrico Gillio Tos,Ann S. Clark,David J. Fischer,David Kagan,Bagna Bao,P. Jorge Chedrese,Stephen S. Palmer +8 more
TL;DR: Oocytes that were ovulated after PDE4 inhibition could be fertilized in vitro at a rate similar to that of oocytes from hCG-induced ovulation, indicating that small molecule PDE 4 inhibitors may be orally active alternatives to hCG as part of a fertility treatment regimen.
Patent
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
Mckenna Sean D,Robert K. Campbell,Xuliang Jiang,Giampiero De-Luca,Meijia Yang,Christie A. Kelton,Stephen J. Arkinstall,Chaomei He,Rene Lynn Schweickhardt +8 more
TL;DR: In this article, the methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy are described, as well as methods of using such molecules for medical applications.
Journal ArticleDOI
Formation of Human IFN-β Complex with the Soluble Type I Interferon Receptor IFNAR-2 Leads to Enhanced IFN Stability, Pharmacokinetics, and Antitumor Activity in Xenografted SCID Mice
Mckenna Sean D,Kristin Vergilis,Antonio Arulanandam,Weishui Weiser,Roustem Nabioullin,Mark Tepper +5 more
TL;DR: Results show that on association with sIFNAR-2, IFN-beta is more stable in vitro and exhibits increased efficacy when administered in vivo, and may provide a method of enhancing the delivery and effectiveness of type I IFNs.